[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myopia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myopia":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,125,0,25,[9,45,74,86,109,135,160,186,212,236,259,289,312,329,355,378,399,420,440,465,489,511,539,554,577],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053297","phase-3-delaying-the-onset-of-nearsightedness-until-treatment-donut-clinical-trial-100053297",false,"NCT07567040","Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial","DONUT","Inclusion Criteria:\n\n* Refractive Error (cycloplegic autorefraction, spherical equivalent, at least one eye, inclusive) 6 years: -0.74 D to +0.75 D 7 and 8 years: -0.74 D to +0.50 D 9 and 10 years: -0.74 D to +0.25 D 11 years: -0.74 D to plano\n* Neither eye has -0.75 D or more myopia, spherical component\n* Anisometropia: Less than 1.50 D difference between OD and OS, cycloplegic autorefraction, spherical equivalent\n* Astigmatism: Less than 1.50 DC in both eyes by cycloplegic autorefraction\n* Successfully complete run-in period: take at least 90% of unit dose artificial tears for 2 to 4 weeks (# of unit-dose vials used divided by # nights since baseline visit must equal 0.90 or greater)\n\nExclusion Criteria:\n\n* If Visit 2 (randomization visit) is not completed within 4 weeks of the baseline, eligibility visit.\n* Presence of strabismus (intermittent or constant) based on unilateral cover test at distance and near\n* Known allergy to atropine\n* Systemic issues that may affect accommodation or convergence (e.g., multiple sclerosis, myasthenia gravis, Graves ophthalmopathy, diabetes mellitus, Parkinson's disease, Down syndrome, etc.)\n* Ocular disease (e.g., congenital glaucoma, retinal disease, nystagmus, amblyopia, etc.)\n* Ocular surgery (e.g., cataracts, strabismus)\n* Any previous myopia prevention\u002Fcontrol therapy (e.g., atropine, soft contact lenses, orthokeratology, myopia control spectacles, etc.) for more than one month\n* Pregnancy by self-report",true,"ALL","6 Years","11 Years",{"count":22,"type":23},664,"ESTIMATED","INTERVENTIONAL",[26],"PHASE3","The aims of this clinical trial will test whether or not the onset of nearsightedness is delayed in a group of children randomized to nightly drops in 0.05% atropine in both eyes, in comparison to children who receiving nightly placebo drops in both eyes. The primary outcome is the two-year cumulative incidence of nearsightedness. The second aim of this project will determine whether atropine is associated with slower eye growth in children receiving nightly drops of atropine versus placebo.",[29],"Myopia",[31],"prevention","RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2026-05-27",{"date":40,"type":23},"2028-05-15",{"name":42,"class":43},"Ohio State University","OTHER",14,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100054152","inhibition-of-myopia-progression-with-optical-devices-100054152","NCT07698977","Inhibition of Myopia Progression With Optical Devices","Inclusion Criteria:\n\n* • Participants must be between 6 and 15 years of age at the start of myopia progression treatment\n\n  * Caucasian ethnicity\n  * Refractive error measured under cycloplegia, expressed as spherical equivalent: between -0.50 Dsph and -10.0 Dsph\n  * Wearing myopia-control glasses while awake\n  * Participation in follow-up examinations every 6 months\n\nExclusion Criteria:\n\n* • Pathological myopia (e.g., myopia onset before age 6, Stickler syndrome)\n\n  * Premature birth before the 32nd week of gestation\n  * Previous eye-opening surgery (e.g., lens removal)\n  * Traumatic eye injury\n  * Known connective tissue disorder (e.g., Marfan syndrome)\n  * Irregular or improper use of progressive-lens glasses\n  * Failure to attend the follow-up examinations scheduled every 6 months","15 Years",{"count":53,"type":23},50,"OBSERVATIONAL","This observational study aims to determine whether optical devices designed to slow myopia progression and\u002For environmental factors can prevent myopia progression in the pediatric and adolescent myopic population.\n\nThe study aims to answer the following questions:\n\n1. How does myopia progression change with age while wearing myopia progression control glasses?\n2. How does myopia progression change while wearing myopia progression-control glasses when environmental factors, such as time spent outdoors and place of residence, are taken into account?\n3. How does myopia progression change at different ages while wearing myopia progression control glasses given a family history of myopia? This will be a self-controlled observational study. Participants who are myopic after cycloplegic refraction will be prescribed DIMS glasses. DIMS stands for \"defocus incorporated multiple segments,\" a specialized optical technology used in spectacle lenses to slow nearsightedness progression in children.\n\nPatients will keep a diary of their subjective symptoms and environmental factors, e.g., time spent outdoors and screen time.\n\nPatients will visit the clinic once every six months for checkups and the following tests:\n\n* Best corrected visual acuity test\n* Stereopsis\n* Automatic refractometry\n* Bulbar axial length measurement\n\nIn a follow-up study, researchers will compare myopia progression with environmental and baseline factors to learn about the long-term effects of DIMS lenses on myopia progression.",[57,29,58],"Myopia Progression","Myopia, Child Myopia Progression",[60,61,62,63,64],"myopia","myopia progression","optical device","DIMS lenses","bulbar axial length","2026-07-07",{"date":35,"type":36},{"date":68,"type":36},"2026-06-02",{"date":70,"type":23},"2027-05-31",{"name":72,"class":43},"Semmelweis University",1,{"id":75,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":76,"targetDuration":4,"studyType":24,"phases":77,"briefSummary":27,"conditions":78,"keywords":79,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":84,"leadSponsor":85,"locationsCount":44},"100636542",{"count":22,"type":23},[26],[29],[31],"2026-07-01",{"date":82,"type":36},"2026-07-02",{"date":38,"type":36},{"date":40,"type":23},{"name":42,"class":43},{"id":87,"slug":88,"hasResults":12,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":73},"100619154","pilot-study-on-the-adaptation-and-tolerance-of-essilor-myopia-control-spectacle-lenses-100619154","NCT07340931","Pilot Study on the Adaptation and Tolerance of Essilor® Myopia-control Spectacle Lenses","STELLAR","Inclusion Criteria:\n\n* Patients aged 6 to 16 years with progressive myopia.\n* Spherical equivalent ≤ -0.50 D under cycloplegia and presence of at least one risk factor (age \\\u003C 10 years, progression ≥ 0.50 D\u002Fyear, axial length increase ≥ 0.2 mm\u002Fyear, high myopia ≤ -6.00 D and\u002For axial length ≥ 26 mm, both parents myopic, at least one parent highly myopic, or Asian origin).\n* Patient covered by the French social security system.\n* Patient and legal guardians providing oral non-opposition to participate in the study.\n\nExclusion Criteria:\n\n* Patients with strabismus, amblyopia, or syndromic myopia","16 Years",{"count":53,"type":23},"This observational pilot study aims to evaluate the adaptation and tolerance of Essilor® Stellest® myopia-control spectacle lenses in children with progressive myopia. The objective is to assess real-life compliance and comfort during lens wear, as these factors are essential for long-term therapeutic adherence and overall visual health outcomes",[29],[60,98,99],"visual correction","compliance","2026-06-23",{"date":102,"type":36},"2026-06-24",{"date":104,"type":36},"2026-01-20",{"date":106,"type":23},"2027-01-20",{"name":108,"class":43},"Nantes University Hospital",{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":12,"sex":18,"minAge":116,"maxAge":20,"enrollmentInfo":117,"targetDuration":4,"studyType":24,"phases":119,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100600315","phase-3-a-rct-of-spectacles-with-aspherical-lenslets-or-005-atropine-for-myopia-control-100600315","NCT07095894","A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control","A Randomized Placebo-controlled Trial of Spectacles With Highly Aspherical Lenslet Target (H.A.L.T.) MAX Technology or 0.05% Atropine to Slow Progression of Myopia in Children","Inclusion Criteria:\n\n1. Age 5 years to \\\u003C12 years at time of enrollment. Children within 4 weeks of their 12th birthday are not eligible.\n2. Refractive error meeting the following by cycloplegic autorefraction:\n\n   * Myopia of 0.75D to 6.00D SER and at least 0.75D in both principal meridians of each eye\n   * Astigmatism \\\u003C2.50D both eyes\n   * Anisometropia \\\u003C1.50D SER\n3. Investigator has confirmed the following regarding best-corrected distance visual acuity (VA) in habitual spectacles or trial frames using the investigator's preferred VA testing method:\n\n   * VA is age normal in both eyes1,2\n   * 5-6 years: approximately 20\u002F32 or better, ≤ 0.24 logMAR, ≥ 73 letters\n   * 7-12 years: approximately 20\u002F25 or better, ≤ 0.14 logMAR, ≥ 78 letters\n   * Interocular difference ≤2 logMAR lines (0.2 logMAR) or ≤ 10 letters\n4. Wearing spectacles by parent report ≥90% of waking hours ≥30 days duration before enrollment. For children who meet all other inclusion criteria but whose single-vision spectacles are broken or lost within the last 90 days, enrollment can proceed as long as the child was wearing their single-vision spectacles ≥90% of waking hours ≥30 days before the spectacles were broken or lost.\n5. Gestational age ≥ 32 weeks.\n6. Birth weight \\>1500 g.\n7. Parent(s) and assenting child understand the study procedures and are willing to accept randomization to atropine 0.05%, HAL lenses, atropine combined with HAL lenses, or placebo (i.e., neither active treatment).\n8. Parent is willing to participate in a 2- to 4-week run-in phase using nightly artificial tear eyedrops in both eyes.\n9. Family can return in 2 to 4 weeks for possible randomization.\n10. Child is willing to refrain from contact lenses for the duration of the study.\n11. Parent has a phone (or access to a phone) and is willing to be contacted by the clinical site staff.\n12. Relocation outside of the area of an active PEDIG site within the next 32 months is not anticipated.\n\nExclusion Criteria:\n\n1. Current or previous pharmacologic or light therapy used for myopia treatment.\n2. Current or prior contact lens wear more than 7 days in the past 12 months\n3. Current or previous use of bifocals, progressive-addition lenses, multi-focal contact lenses, or focus- or contrast-modifying spectacle lenses.\n4. Current or previous use of orthokeratology, rigid gas permeable, or other contact lenses used to slow myopia progression.\n5. Current or previous myopia control treatment or other uses of atropine, pirenzepine or other anti-muscarinic agents.\n6. Known atropine allergy\n7. Known allergy to shellfish\n8. Abnormality of the cornea, lens, central retina, iris, or ciliary body\n9. Current constant or intermittent strabismus (phorias are acceptable)\n10. Verified history of amblyopia or nystagmus.\n11. Prior strabismus, intraocular, or refractive surgery\n12. Down syndrome or cerebral palsy\n13. Diseases known to affect accommodation, vergence, or ocular motility (e.g., multiple sclerosis, Graves' disease, myasthenia gravis, diabetes mellitus)\n14. Any condition that, in the judgment of the investigator, could influence refractive error development.\n15. Existing conditions in the opinion of the investigator that may affect the long-term health of the eye or require regular pharmacologic treatment that may adversely interact with study medication (e.g., JIA, glaucoma, pre-diabetes).\n16. Inability to comprehend and\u002For perform any study-related procedures.\n17. Individuals who are pregnant, lactating, or intending to become pregnant within the next 30 months.\n\n    a. A negative urine pregnancy test at randomization and the 6-, 12-, 18-, and 24-month follow-up visits will be required for individuals who have experienced menarche (at least one menstrual cycle).\n18. Immediate family member (spouse, biological or legal guardian, child, sibling, parent) who is investigative site personnel directly affiliated with this study or who is an employee of the Jaeb Center for Health Research.\n19. Sibling of, or living in the same household as, another child who is concurrently enrolled in the study.","5 Years",{"count":118,"type":23},348,[26],"To date, randomized trials of low-concentration atropine eyedrops and specially designed spectacle lenses to slow the progression of myopia are limited in number and results are inconsistent in non-Asian children.\n\nAlthough results of some recent randomized clinical trials outside the US are promising, additional studies in children are needed to test the safety and efficacy of low-concentration atropine and specially designed spectacle lenses as treatments to slow the progression of myopia during the peak years for eye growth.\n\nAfter a run-in phase to demonstrate adherence with nightly eyedrops (artificial tears) and spectacle correction, children 5 to \\\u003C12 years old with myopia of 0.75D to 6.00D cycloplegic spherical equivalent refractive error (SER) and at least 0.75D myopia in both principal meridians of each eye will be randomized in a 2x2 factorial design to treatment with 1) nightly 0.05% atropine or placebo eyedrops, and 2) spectacles with highly aspherical lenslet target (H.A.L.T.) MAX technology or single vision spectacles, and followed every six months for 24 months. Change in axial length over 24 months and change in SER over 24 months are the primary and secondary outcomes, respectively.\n\nAll children will return for a visit at 30 months (after 6 months of no treatment other than single-vision spectacles alone between 24 and 30 months).\n\nThe study is funded by the National Eye Institute, part of the NIH, and coordinated by the Jaeb Center for Health Research on behalf of PEDIG. Essilor International, a subsidiary of EssilorLuxottica, the manufacturer of Spectacle lenses with H.A.L.T.\\* MAX technology, is providing the eyeglasses and financial support for the study. The 0.05% atropine eye drops used in the study are manufactured by Imprimis Rx, a subsidiary of Harrow, Inc.",[29],[60,123,124,125],"spectacles","atropine","pediatric",{"date":127,"type":36},"2026-06-26",{"date":129,"type":36},"2026-06-01",{"date":131,"type":23},"2029-06-01",{"name":133,"class":43},"Jaeb Center for Health Research",17,{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":141,"enrollmentInfo":142,"targetDuration":144,"studyType":54,"phases":4,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":73},"100641492","functional-vision-and-quality-of-life-in-a-modern-society---with-emphasis-on-myopia-and-cerebral-visual-impairment-among-youth-100641492","NCT07653074","Functional Vision and Quality of Life in a Modern Society - With Emphasis on Myopia and Cerebral Visual Impairment Among Youth","Inclusion Criteria:\n\n* Healthy children\n\nExclusion Criteria:\n\n* Children with ophthalmological diagnosis followed frequently by the ophthalmological clinic","17 Years",{"count":143,"type":23},300,"1 Day","Society has become increasingly digital, and many everyday services have been replaced by digital self-service solutions. This puts greater demands on our vision and our ability to interpret what we see. At the same time, the number of children with nearsightedness (myopia) has increased rapidly. In some parts of Asia, as many as 60-70% of students in seventh grade are nearsighted (1), and a similar trend may develop in Europe.\n\nNearsightedness is becoming a growing challenge in pediatric eye care. High myopia can lead to complications that require early detection and prevention. There are now several ways to slow down its progression, such as special contact lenses, glasses, and eye drops (2). However, the scientific evidence for these treatments varies, and there are currently no national or Nordic guidelines on how to use them. In addition, myopia may have a major impact on children's quality of life.\n\nCurrently, there is no validated Swedish questionnaire that measures vision related quality of life across all age groups in children and adolescents. To address this, researchers in the United States developed the Pediatric Eye Questionnaire (PedEyeQ) in 2019 (3). It is already available in English and Spanish and takes into account both the child's and the parent's perspectives on vision and daily life.\n\nThe aim of this study is to translate, culturally adapt and test the PedEyeQ in Swedish children and adolescents, and to investigate how common refractive errors, especially nearsightedness - are today compared to 20-30 years ago.\n\nThe study will include 300 healthy children and adolescents aged 0-17 years, divided into three age groups: 0-4 years, 5-11 years, and 12-17 years. Participants will be recruited through child health centers, preschools, and schools in the Örebro region.\n\nAll participants will visit the eye clinic for a detailed eye examination, including:\n\n* Testing distance and near visual acuity\n* Measuring eye refraction (with and without eye drops that temporarily relax the eye's focusing muscles)\n* Imaging the retina using Optical Coherence Tomography (OCT)\n* Measuring eye length and corneal shape\n* Checking eye pressure and contrast sensitivity\n\nChildren and parents will also answer questions about how the child's vision affects everyday life and wellbeing. For the youngest children (0-4 years), only parents will answer the questions.\n\nThe PedEyeQ will be translated into Swedish following the International Society for Pharmacoeconomics and Outcome Research (ISPOR) (4) guidelines to make sure it is culturally relevant and easy to understand. The Swedish version will then be tested to ensure it is accurate and reliable.\n\nAll information collected in the study will be stored securely and anonymously. The results will also be compared with data from a similar cohort conducted in the 1990s to see if vision problems have become more common over time (5).\n\nThis project will provide new knowledge about children's vision and quality of life in Sweden. A validated Swedish version of the PedEyeQ can be used both in healthcare and research to better understand how vision affects children's daily lives. The study will also offer updated information on the frequency of refractive errors among Swedish children and adolescents - knowledge that is essential for developing preventive strategies and improving eye care for the future.",[29,147],"Quality of Life",[149,60,150],"Quality of life","Sweden","2026-06-11",{"date":153,"type":36},"2026-06-17",{"date":155,"type":36},"2024-10-27",{"date":157,"type":23},"2029-05-30",{"name":159,"class":43},"Region Örebro County",{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":24,"phases":169,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":182,"completionDateStruct":183,"leadSponsor":184,"locationsCount":4},"100643616","a-comparative-study-of-the-efficacy-of-myopia-control-lenses-with-different-mechanisms-on-controlling-myopia-progression-in-patients-with-intermittent-exotropia-100643616","NCT07642934","A Comparative Study of the Efficacy of Myopia Control Lenses With Different Mechanisms on Controlling Myopia Progression in Patients With Intermittent Exotropia","Inclusion Criteria:\n\n1. Participants aged 6 to 12 years (6 ≤ age ≤ 12 years). Written informed consent from legal guardians is mandatory.\n2. Patients with basic-type intermittent exotropia (IXT) meeting all the following criteria:\n\n   1. Intermittent or constant exotropia at the distance of 6 meters, and intermittent exotropia or esophoria at the near distance of 33 centimeters;\n   2. Distance exodeviation ≥ 10 prism diopters (PD) measured via the prism and alternate cover test (PACT);\n   3. The difference between near and distance deviation ≤ 10 PD.\n3. Based on cycloplegic spherical equivalent (SE), the myopic refractive error of both eyes ranges from -6.0 D to -0.5 D.\n4. The logMAR value of monocular distance best-corrected visual acuity (BCVA) measured by the ETDRS chart is ≤ 0.2, and no amblyopia is present.\n5. Parents and children are willing to participate in this clinical trial and can complete the entire study protocol.\n6. Children have healthy eyes without organic ocular diseases.\n\nExclusion Criteria:\n\n1. Participants who have worn myopia control glasses or received other myopia interventions, including low-concentration atropine and phototherapy instruments, within the past 6 months (excluding DIMS and DOT glasses).\n2. Those with severe systemic diseases or cognitive impairment that hinders follow-up attendance and clinical examinations.\n\n4\\. Subjects with astigmatism of ≥ 2 diopters (D) in either eye after cycloplegia; individuals enrolled in other interventional trials.\n\n5\\. Patients with active ocular inflammation in either eye. 6. Those diagnosed with ocular diseases or presenting with clinically significant abnormalities on ophthalmic examinations.\n\n7\\. Participants are currently receiving visual function training or other clinical interventions for intermittent exotropia.\n\n8\\. Individuals who decline to complete the 1-year follow-up period.","12 Years",{"count":168,"type":23},120,[170],"NA","The goal of this clinical trial is to compare the efficacy of myopia control lenses with different working principles in patients with intermittent exotropia aged 6 to 12 years. The main questions it aims to answer are:\n\nAre there any differences in the clinical outcomes of DIMS and DOT glasses between children with intermittent exotropia and those with simple myopia (without intermittent exotropia)? Do DIMS and DOT glasses differ in their myopia control efficacy among children with intermittent exotropia? Does wearing DIMS or DOT glasses affect the binocular visual function of children with intermittent exotropia?",[173,29],"Intermittent Exotropia",[175,176,177,178],"Intermittent exotropia","Myopia control","DIMS","DOT","NOT_YET_RECRUITING","2026-06-09",{"date":151,"type":36},{"date":129,"type":23},{"date":70,"type":23},{"name":185,"class":43},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":17,"sex":18,"minAge":193,"maxAge":166,"enrollmentInfo":194,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":73},"100642655","longitudinal-measurements-of-visual-diet-in-children-100642655","NCT07642999","Longitudinal Measurements of Visual Diet in Children","VEET","Inclusion Criteria:\n\n* Age: 7-12 years old (inclusive)\n* Astigmatism of \\\u003C 1.50D\n* Stereopsis equal or better 100 seconds of arc\n* Normal binocular functions.\n\nIn addition, for the Myopic group:\n\n\\- Cycloplegic autorefraction (spherical equivalent, SEQ) between -0.50D and -6.00D, who are not currently pursuing nor intending to start myopia control at the time of enrollment.\n\nFor the non-myopic group:\n\n\\- SEQ between plano and +2.50D.\n\nExclusion Criteria for both groups:\n\n* History of refractive surgery or myopia control\n* Binocular abnormalities\n* Ocular and systemic pathologies\n* Developmental delay\n* Unable to wear the VEET at home for 8 days every 6 months for 3 years\n* Pre-term birth (\\\u003C 34 weeks of gestational age).","7 Years",{"count":195,"type":23},60,"Myopia is a leading cause of visual impairment worldwide, with prevalence rising rapidly among children. Growing evidence suggests that environmental and behavioral factors play a dominant role in ocular growth; however, current studies typically isolate single components of the visual environment, such as near work or light intensity, limiting investigators' understanding of how multiple visual stimuli interact within individuals over time. The retina is continuously exposed to a dynamic \"visual diet,\" encompassing viewing distance, illuminance, spectral composition of light, and temporal viewing patterns, as well as associated visuomotor responses such as eye vergence and pupil dynamics. A critical barrier to myopia prevention is the lack of longitudinal, quantitative measurements that integrate these factors in real-world settings during childhood ocular development.\n\nThe long-term goal of this project is to prevent myopia onset and slow myopia progression through individualized, patient-centered monitoring and modification of the visual diet. The overall objective of this proposal is to longitudinally characterize visual diet and visuomotor behavior in children and to identify the most influential environmental and physiological factors driving myopia onset and progression. The investigators will conduct a 3-year longitudinal observational study enrolling 60 children aged 7-12 years, including myopic children and non-myopic children stratified by risk of myopia progression.",[29,198,199,200,201,202,203,204],"Visual Diet","Pupil","Viewing Distance","Illuminance","Wavelength","Vergence","Accommodative Facility",{"date":151,"type":36},{"date":207,"type":23},"2026-06-08",{"date":209,"type":23},"2031-06",{"name":211,"class":43},"State University of New York College of Optometry",{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":17,"sex":18,"minAge":218,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":222,"conditions":223,"keywords":227,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":232,"leadSponsor":234,"locationsCount":73},"100641841","corneal-epithelial-thickness-mapping-by-anterior-segment-optical-coherence-tomography-in-patients-with-refractive-errors-100641841","NCT07647146","Corneal Epithelial Thickness Mapping by Anterior Segment Optical Coherence Tomography in Patients With Refractive Errors","Inclusion Criteria:\n\n* Age ≥ 18 years-\n* Patients diagnosed with myopia or hyperopia by refraction\n* Clear cornea with no evidence of corneal pathology\n* Ability to undergo reliable anterior segment imaging\n\nExclusion Criteria:\n\n* Inability to fixate or follow instructions\n* Family history of keratoconus\n* Glaucoma,Cataract\n* Previous ocular surgery including refractive surgery\n* Keratoconus or suspected corneal ectasia\n* Corneal opacities or scars\n* Contact lens wear within the last two weeks\n* Ocular trauma\n* systemic disease affecting the cornea ( Such as diabetes)","18 Years","99 Years",{"count":221,"type":23},360,"This study evaluates corneal epithelial thickness using anterior segment optical coherence tomography (AS-OCT) in patients with refractive errors. It aims to assess the relationship between epithelial thickness patterns and different types of refractive errors.",[29,224,225,226],"Hyperopia","Astigmatism","Emmetropia",[228],"Corneal epithelial thickness, AS-OCT, anterior segment optical coherence tomography, refractive errors, myopia, hyperopia, astigmatism, cornea",{"date":230,"type":36},"2026-06-15",{"date":80,"type":23},{"date":233,"type":23},"2027-05-01",{"name":235,"class":43},"Sohag University",{"id":237,"slug":238,"hasResults":12,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":166,"enrollmentInfo":243,"targetDuration":4,"studyType":24,"phases":245,"briefSummary":246,"conditions":247,"keywords":249,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":73},"100592629","virtual-far-sight-reading-device-for-myopia-intervention-among-pre-myopic-children-100592629","NCT06995911","Virtual Far-sight Reading Device for Myopia Intervention Among Pre-myopic Children","A Randomized Controlled Clinical Trial on the Efficacy and Safety of the Virtual Far-sight Reading Device for Myopia Intervention in Pre-myopic Children","Inclusion Criteria:\n\n* Age: 6-12 years (inclusive), gender unrestricted.\n\n  * Worse eye cycloplegic spherical equivalent refraction (SER): -0.5 D \\\u003C SER ≤ +0.75 D; Cylinder ≤ -1.5 D in both eyes; Interocular anisometropia ≤ 1.5 D ③ Visual acuity: Best-corrected visual acuity (BCVA) ≤ 0.1 logMAR in both eyes. ④ Family history: At least one parent with myopia.\n\n    * Intraocular pressure (IOP): 10-21 mmHg in both eyes; Interocular IOP difference ≤ 5 mmHg\n\n      ⑥ Compliance: Commitment to daily home use of the Far-Image Light Field Desk per protocol, immediate notification to investigators if unable to comply, and completion of scheduled follow-ups.\n\n      ⑦ Informed consent: Signed assent form (minor) and written informed consent from legal guardian.\n\nExclusion Criteria:\n\n* Ocular comorbidities affecting vision\u002Frefractive development: Marfan syndrome; Lens pathologies (e.g., cataracts); Glaucoma; retinal detachment; retinopathy of prematurity\n\n  * Systemic diseases: Immune\u002FCNS disorders; Down syndrome; Severe cardiopulmonary\u002Fhepatic\u002Frenal dysfunction; Uncontrolled asthma\n\n    * Ocular abnormalities: Manifest strabismus; Binocular vision dysfunction; Pathological ocular changes or active ocular inflammation ④ Recent myopia interventions (within 3 months prior to screening): Orthokeratology; multifocal contact lenses; Functional spectacles, red-light therapy\n\n      ⑤ Medications affecting efficacy evaluation (within 3 months): Anticholinergics (e.g., atropine, pirenzepine); Cholinergics (e.g., pilocarpine)\n\n      ⑥ Participation in other clinical trials within 3 months.\n\n      ⑦ Contraindications\u002Fallergies to cycloplegics or study-related medications.\n\n      ⑧ Chronic psychiatric disorders or cognitive impairment.\n\n      ⑨ Other conditions deemed unsuitable by investigators.",{"count":244,"type":23},80,[170],"This clinical trial wants to find out if the Virtual Far-sight Reading Device can help prevent or slow down myopia progression in children and teenagers with pre-myopia. We also want to know what makes this treatment work better for some participants and check for any eye or body-related side effects over time.\n\nMain questions:\n\nCan using the Virtual Far-sight Reading Device reduce the risk of myopia? Is the device safe to use every day for up to 6 months?\n\nWhat we'll do:\n\nResearchers will compare two groups of children:\n\nGroup A: Uses the device for reading\u002Fwriting (at least 1 hour daily) Group B: Does regular reading\u002Fwriting without the device After 90 days, the groups will switch to see if the results stay the same.\n\nParticipants will:\n\n* Have free eye checkups 3 times over 6 months\n* Use the device during homework time (if in the desk group)\n* Report any eye discomfort or problems",[29,248],"Pre-myopia",[29,248],"2026-05-21",{"date":252,"type":36},"2026-05-26",{"date":254,"type":36},"2025-06-01",{"date":256,"type":23},"2026-05-31",{"name":258,"class":43},"Shanghai Eye Disease Prevention and Treatment Center",{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":268,"conditions":269,"keywords":275,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":73},"100563464","artificial-intelligence-for-highly-myopic-cataract-100563464","NCT06616506","Artificial Intelligence for Highly Myopic Cataract","AI-HMC","Inclusion Criteria:\n\nAxial length ≥ 26 mm and patients with high myopia complicated by cataracts who visit our hospital.\n\nPreoperative anterior segment photography and cataract severity assessment, along with fundus OCT examination, have been performed.\n\nIf surgical treatment is conducted, the postoperative follow-up period should be no less than 1 month.\n\nThere are no missing clinical data before and after the surgery.\n\nExclusion Criteria:\n\nPatients who are unable to cooperate with the required examinations for this study.",{"count":267,"type":23},500000,"This study aims to establish a multi-center artificial intelligence model for the accurate calculation of intraocular lens and its clinical application in highly myopic cataract, so as to improve the accuracy of the prediction of postoperative diopter in highly myopic cataract patients.",[270,271,29,272,273,274],"Cataract","High Myopia","Automatic Judgement","Risk Reduction","Diagnoses Disease",[276,277,278,279],"highly myopic cataract","artificial intelligence","cataract","big data","2026-05-06",{"date":282,"type":36},"2026-05-11",{"date":284,"type":36},"2016-01-01",{"date":286,"type":23},"2035-12-31",{"name":288,"class":43},"Shanghai High Myopia Study Group",{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":166,"enrollmentInfo":296,"targetDuration":4,"studyType":24,"phases":298,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":73},"100610574","mobility-performance-in-daily-activities-among-children-wearing-spectacle-lenses-100610574","NCT07229352","Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses","Mobility Performance in Daily Activities Among Children Wearing Single Vision and Myopia Control Spectacle Lenses","Inclusion Criteria:\n\nA participant is eligible for inclusion in the study if they meet the following criteria:\n\n* Are between the ages of 6 and 12 years of age (inclusive) at the time of informed consent\u002Fassent.\n* Can achieve a corrected visual acuity of 20\u002F20 best-corrected (or equivalent logMAR).\n* Have undergone a self-reported oculo-visual examination within the past two years.\n* Have no active ocular disease.\n* Are willing and able to adhere to instructions, study procedures, and maintain the appointment schedule.\n* Have not previously worn or participated in myopia control contact lenses for more than one month and are not currently undergoing any form of myopia control treatment.\n* The subject's parent(s) or legal guardian(s) must read, understand, and sign the Statement of Informed Consent and receive a fully executed copy of the form.\n\nExclusion Criteria:\n\nA participant will be excluded from the study if they meet any of the following conditions:\n\n* Have any systemic disease that affects ocular health.\n* Are currently using or have used, within the past 7 days, any systemic or topical medications that may impact ocular health.\n* Are currently using or have used any topical ophthalmic agents with anti-muscarinic properties within 7 days prior to enrollment or at any point during the study. This includes, but is not limited to, atropine, scopolamine, pirenzepine, tropicamide, cyclopentolate, and homatropine.\n* Have used any oral agents with anti-muscarinic properties for a chronic period (2 months or more) or short-term (within 7 days prior to enrollment). This includes, but is not limited to, gastrointestinal anti-spasmodic medications containing atropine, hyoscyamine, and dicyclomine.\n* Have known developmental delays.\n* Have participated in another clinical study in the last 7 days",{"count":297,"type":23},20,[170],"The aim of this study is evaluate and compare the mobility performance of children in daily activities while wearing single vision spectacle lenses (control) versus myopia control spectacle lenses (test).",[29,57,301],"Juvenile Myopia","2026-04-29",{"date":304,"type":36},"2026-04-30",{"date":306,"type":36},"2026-02-02",{"date":308,"type":23},"2027-07-01",{"name":310,"class":311},"SightGlass Vision, Inc.","INDUSTRY",{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":17,"sex":18,"minAge":193,"maxAge":319,"enrollmentInfo":320,"targetDuration":4,"studyType":24,"phases":321,"briefSummary":322,"conditions":323,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":324,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":328,"locationsCount":73},"100610575","childrens-viewing-behavior-100610575","NCT07229365","Children's Viewing Behavior","Children's Viewing Behavior in Myopia Control Spectacles","Inclusion Criteria:\n\nA person is eligible for inclusion in the study if he\u002Fshe:\n\n* Is 7-14 years of age, inclusive\n* Requires spherical spectacle lenses within the power range available for the study lenses\n* Parent\u002Fguardian has read and understood the informed consent form, and the child has provided age-appropriate assent\n* Is willing and able to follow instructions and maintain the appointment schedule\n* Is correctable to a visual acuity of 20\u002F40 or better (in each eye) with their habitual vision correction or 20\u002F20 best corrected\n* Has had a self-reported oculo-visual examination in the last two years\n* Spectacle cylinder of ≤ -0.75DC in both eyes\n\nExclusion Criteria:\n\nA person will be excluded from the study if he\u002Fshe:\n\n* Is unable to complete the necessary study activities\n* Has any systemic disease affecting ocular health\n* Is using any systemic or topical medications (including pharmaceutical myopia control therapy) that will affect ocular health\n* Is aphakic","14 Years",{"count":297,"type":23},[170],"The aim of this study is to investigate the area of the spectacle lens in which a subject is viewing through regardless of task being performed.",[29,57,301],{"date":304,"type":36},{"date":326,"type":36},"2025-12-22",{"date":308,"type":23},{"name":310,"class":311},{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":17,"sex":18,"minAge":218,"maxAge":336,"enrollmentInfo":337,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":339,"conditions":340,"keywords":345,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":73},"100567556","study-on-the-diagnostic-efficacy-of-icl-selection-and-prediction-depth-model-based-on-eye-images-100567556","NCT06669728","Study on the Diagnostic Efficacy of ICL Selection and Prediction Depth Model Based on Eye Images","Diagnostic Efficacy of Deep Neural Network Algorithm Based on Preoperative Scheimpflug-based Anterior Segment Image for Implantable Collamer Lens Selection and Prediction","Inclusion Criteria:\n\n1. Aged 18-45 years ;\n2. Myopia, with or without astigmatism, annual diopter change ≤ 0.50 D for 2 consecutive years ;\n3. Anterior chamber depth ≥ 2.80 mm ;\n4. Corneal endothelial cell count ≥ 2000 \u002F mm2, stable cell morphology ;\n5. There were no other ocular diseases that significantly affected vision and \u002F or systemic organic lesions that affected surgical recovery.\n\nExclusion Criteria:\n\n1. There were no other ocular diseases that significantly affected vision and \u002F or systemic organic lesions that affected surgical recovery;\n2. Have a history of corneal refractive surgery or intraocular surgery ;\n3. Corneal endothelial cell count is low ;\n4. Those with systemic diseases ;\n5. Lactating or pregnant women.","45 Years",{"count":338,"type":23},326,"To evaluate the diagnostic efficacy of deep learning network model in implantable collamer lens selection and prediction in a multicenter cross-sectional study",[341,342,343,29,344],"Posterior Chamber Phakic Intraocular Lens","Vault","Deep Neural Network","Anterior Chamber Angle",[341,342,343],"2026-04-21",{"date":348,"type":36},"2026-04-24",{"date":350,"type":36},"2021-01-02",{"date":352,"type":23},"2027-08-31",{"name":354,"class":43},"Second Affiliated Hospital of Nanchang University",{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":18,"minAge":193,"maxAge":166,"enrollmentInfo":362,"targetDuration":4,"studyType":24,"phases":364,"briefSummary":365,"conditions":366,"keywords":367,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":4},"100635007","myopia-control-using-novel-soft-contact-lenses-100635007","NCT07547085","Myopia Control Using Novel Soft Contact Lenses","Advancing Myopia Control in Children: A Randomized Controlled Trial of Two Novel Daily Disposable Contact Lenses","Inclusion Criteria:\n\n* • Age at enrolment: 7 - 12 (both inclusive) years old Hong Kong Chinese schoolchildren\n\n  * Refractive errors in terms of spherical equivalent refraction (SER) determined by cycloplegic autorefraction: -0.75 diopters (D) to -5.00D in both eyes\n  * Astigmatism: equal or less than -1.00D\n  * Anisometropia: equal or less than -1.75D\n  * Previous myopia progression:\n\n    * -0.50D (in SER) per year or more in 1 eye or both eyes OR Axial length elongation: 0.27mm\u002Fyear in 1 eye or both eyes\n    * If myopia is initially detected during screening, eligibility requires an SER below the 3rd percentile curve of refraction in either or both eyes (4)\n  * Best corrected visual acuity: better than 0.04 LogMAR in both eyes\n  * Ocular health: no abnormalities in both internal and external ocular health\n  * Systemic health: no systemic interference with ocular vision functioning\n  * Binocular vision: no strabismus and other binocular abnormalities\n  * No medication or supplements that affect eye growth\n  * Normal colour vision\n  * No previous use of myopic control interventions such as red-light therapy, atropine, orthokeratology, specialized spectacle lenses and contact lenses and oral supplements for myopic control\n  * Agree to maintain the visit schedule and be able to keep all appointments as specified in the informed assent and consent forms throughout study duration.\n  * Agree to accept either the control or study lens as assigned by the randomization scheme\n  * Agree to wear the assigned contact lenses for a minimum of 10 hours per day, at least 6 days per week, for the duration of the 2-year study and to inform the study investigator if this schedule is interrupted. Wearing time may be modified by the study staff for health reasons\n  * Agree to adhere to contact lens use requirements throughout study duration\n  * Acceptance of the masked study design\n\nExclusion Criteria:\n\n* Contraindications for soft contact lenses\n* Dry eye with drug intervention within 30 days\n\n  * Regular use of ocular medication (prescription or over-the-counter), artificial tears, or wetting agents due to dryness, allergies or other conditions that hinder the contact lens wear\n  * Current use of systemic medications that may significantly affect contact lens wear, tear film production, pupil size, accommodation, or refractive state. These include, but not limited to, long term use of nasal decongestants (e.g., pseudoephedrine, phenylephrine), antihistamines (e.g., chlorpheniramine, diphenhydramine, Prednisolone or Ritalin (methylphenidate)\n  * Pre-existing systemic and ocular disease that had an influence on contact lens wearing\n  * History of ocular injury or surgery\n  * Prior use of myopic control interventions such as red-light therapy, atropine, orthokeratology, specialized spectacle lenses and contact lenses and oral supplements\n  * Allergy to cyclopentolate eye drops\n  * Subjects who, in the judgment of the Investigator, are unable to cooperate and follow instructions during eye examination",{"count":363,"type":23},126,[170],"The goal of this study is to investigate the myopic control efficacy of two study soft contact lenses in children. Participants will be prescribed Lens A, Lens B or single vision contact lenses for the first year. Participants in single vision contact lenses group will switch to Lens A at 12 months. All participants will then continue lens wear for an additional 12 months. Their cycloplegic refraction and axial length will be monitored every 6 months for 2 years.",[29],[176,368],"soft contact lenses","2026-04-17",{"date":371,"type":36},"2026-04-23",{"date":373,"type":23},"2026-04-16",{"date":375,"type":23},"2029-07-14",{"name":377,"class":43},"The Hong Kong Polytechnic University",{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":385,"enrollmentInfo":386,"targetDuration":4,"studyType":24,"phases":388,"briefSummary":389,"conditions":390,"keywords":391,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":4},"100635006","choroidal-response-to-the-modified-defocus-incorporated-multiple-segments-spectacle-lenses-100635006","NCT07547072","Choroidal Response to the Modified Defocus Incorporated Multiple Segments Spectacle Lenses","Choroidal Responses to the Modified Defocus Incorporated Multiple Segments (DIMS) Spectacle Lenses","Inclusion Criteria:\n\n* Hong Kong Chinese\n* Age at enrolment: 6 - 13 years\n* Myopia in spherical power: -1.00D to -5.00D in both eyes\n* Astigmatism: equal or less than 2.00D\n* The sum of spherical power and astigmatism: equal or less than -7.00D\n* Anisometropia (spherical equivalent refraction (SER)): equal or less than 1.50D\n* Previous myopia progression (valid documentation dated within 2 years before screening):\n\n  * -0.50D (SER) per year or more in both eyes OR Axial length elongation: 0.27mm\u002Fyear in both eyes\n  * If myopia is initially detected during screening, eligibility requires myopia (in SER) below the 3rd percentile curve of refraction in both eyes.12\n* Best corrected visual acuity: LogMAR 0.04 or better in both eyes\n* Ocular health: no abnormalities in both internal and external ocular health\n* Binocular vision: no strabismus and other binocular abnormalities\n* Normal colour vision\n* Willing to wear the study spectacles all the time (10 hours per day, for 7 days per week)\n\nExclusion Criteria:\n\n* Previous or current treatment for myopia control (e.g., red-light therapy, atropine, orthokeratology, specialized spectacle lenses and contact lenses and oral supplements for myopic control)\n* Existing or past eye diseases or surgeries (e.g., strabismus surgery, amblyopia, oculomotor nerve palsies, corneal disease, intraocular disease, etc.) that may have an impact on vision or visual development\n* Long-term medication (intake at least 3 days\u002Fweek) or medication\u002Fsupplements that affect eye health\n* Systemic diseases that may have an impact on vision or visual development (e.g., endocrine, cardiac and respiratory diseases, diabetes, Down syndrome, etc.)\n* Allergic to cyclopentolate eye drops\n* Individuals who, in the judgment of the Investigator, are unable to cooperate and follow instructions during eye examination.","13 Years",{"count":387,"type":23},108,[170],"The goal of this study is to investigate the short-term changes in choroidal thickness and efficacy of the study spectacle lenses in children. Participants will be prescribed with a pair of study spectacle lenses for daily use and visit the clinic once every week for the first month for checkup and tests. After the first month of follow-up, participants will visit at 1 month, 6- and 12-month for checkup. Choroidal thickness, axial length and refractive errors will be monitored.",[29],[29,392],"Choroidal thickness",{"date":371,"type":36},{"date":395,"type":23},"2026-04-25",{"date":397,"type":23},"2028-02-29",{"name":377,"class":43},{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":17,"sex":18,"minAge":406,"maxAge":218,"enrollmentInfo":407,"targetDuration":406,"studyType":54,"phases":4,"briefSummary":409,"conditions":410,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":413,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":73},"100635058","evaluation-of-a-county-based-eye-health-service-model-in-rural-chinese-children-100635058","NCT07547748","Evaluation of a County-Based Eye Health Service Model in Rural Chinese Children","Evaluation of a County-Based Eye Health Service Model for Preventing and Controlling Avoidable Visual Impairment in Rural Chinese Children","Inclusion Criteria:\n\n* Aged 3 to 18 years; Enrolled in schools within the study areas, including kindergartens, primary schools, junior high schools, and senior high schools, in Yangxi County, Jiexi County, Huidong County, and Yingde City of Guangdong Province, as well as Fengqing County of Yunnan Province, or are children and adolescents who are permanent residents within these jurisdictions.\n* Written informed consent has been provided by their legal guardians.\n* For children aged 8 years and older, assent from the child is also required.\n\nExclusion Criteria:\n\n* Presence of severe systemic diseases (such as severe congenital heart disease or intellectual developmental disorders) that preclude cooperation with ophthalmic examinations.\n* Refusal by the legal guardian to participate, or inability of the legal guardian to cooperate with scheduled follow-up visits.","3 Years",{"count":408,"type":23},20000,"This project proposes to conduct a prospective, multicenter registry study in rural China to evaluate, under real-world conditions, the implementation effectiveness of an integrated child eye health service model centered at the county level and coordinated across county, township, village, and school tiers. The target population will include all children and adolescents within participating counties, and the primary exposure will be the annual coverage and implementation intensity of this service model. The study will focus on its impact on clinical outcomes such as refractive error correction rates and referral rates following eye disease screening, while also examining annual trends in disparities in access to different eye care services. Through long-term and systematic observation, the project aims to clarify the sustained effects of this eye health service model on improving the management of pediatric eye diseases, enhancing visual function, and promoting health equity, thereby providing evidence-based support for optimizing the rural child eye care system in China.",[29,411,412],"Strabismus","Eye Health",{"date":371,"type":36},{"date":415,"type":36},"2025-01-01",{"date":417,"type":23},"2028-12-31",{"name":419,"class":43},"Zhongshan Ophthalmic Center, Sun Yat-sen University",{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":427,"enrollmentInfo":428,"targetDuration":4,"studyType":24,"phases":430,"briefSummary":431,"conditions":432,"keywords":4,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":73},"100634128","efficacy-of-multi-type-photolithography-flat-microstructure-lenses-for-childhood-myopia-control-100634128","NCT07535658","Efficacy of Multi-Type Photolithography Flat Microstructure Lenses for Childhood Myopia Control","Comparative Efficacy and Safety of Multi-Type Photolithography Flat Microstructure Spectacle Lenses Versus Spectacle Lenses With Aspherical Lenslets for Myopia Control in Chinese Children: A 12-Month Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age: 6 years ≤ age ≤ 8 years (calculated based on the informed consent date);\n2. The spherical equivalent (SE) of both eyes is 0D to +1.00D (inclusive of boundary values) after cycloplegia;\n3. Astigmatism: Cylindrical power of both eyes ≤ 1.00D;\n4. Anisometropia: Difference in spherical equivalent between both eyes ≤ 1.00D;\n5. Corrected visual acuity: Best corrected visual acuity (BCVA) of both eyes ≥ 1.0 (decimal notation, 5m);\n6. General health status: No systemic syndromes that affect ocular development; no long-term use of growth hormone, corticosteroids, or antiepileptic drugs;\n7. Previous intervention: No use of any myopia control methods within the past 3 months, including but not limited to: multifocal glasses, atropine eye drops, red light therapy, acupuncture, etc.\n8. Compliance with spectacle wear: Parents ensure that the child wears glasses for ≥8 hours per day;\n9. Follow-up capability: Ability to attend scheduled follow-ups for 12 months (4 visits in total);\n10. Informed consent from guardian: Legal guardian signs the informed consent form; children also sign the assent form.\n\nExclusion Criteria:\n\n1. History or presence of glaucoma, corneal disease, or other ocular organic disease, or acute or chronic ocular inflammation;\n2. Combined with systemic major diseases, mental diseases, or systemic collagen metabolism diseases;\n3. Used any myopia intervention drugs or devices in the past 3 months;\n4. Those who have participated in other similar clinical studies in the past 3 months;\n5. Diagnosis of amblyopia, constant strabismus, and other congenital eye diseases;\n6. Those who are allergic to the lens material or products related to the study;\n7. Allergy to mydriatic agents and related ophthalmic medications;\n8. Allergic to photochromic materials or related dyes; taking photosensitizing drugs; suffering from photo-induced skin or neurological disorders;\n9. Unable to understand the study content or unable to cooperate with the follow-up;\n10. Other reasons why the research doctor believes the patient is not suitable for the study.","8 Years",{"count":429,"type":23},255,[170],"The goal of this clinical trial is to learn if photolithographic flat microstructure lenses work to prevent myopia in children. It will also learn about the safety of different designs of photolithographic flat microstructure lenses. The main questions it aims to answer are:\n\nAre photolithography flat microstructure lenses effective and safe in preventing myopia in children? Does the depth of tinted lenses affect visual quality? Researchers will compare photolithography flat microstructure lenses to a spectacle lenses with aspherical lenslets to see if photolithography flat microstructure lenses works to prevent myopia in children.\n\nParticipants will:\n\nWear photolithography flat microstructure lenses or Spectacle Lenses with Aspherical Lenslets more than 8H per day for 1 year.\n\nVisit the clinic once every 3 months for checkups and tests.",[29],"2026-04-14",{"date":369,"type":36},{"date":436,"type":23},"2026-04-15",{"date":438,"type":23},"2027-12-31",{"name":258,"class":43},{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":385,"enrollmentInfo":447,"targetDuration":4,"studyType":24,"phases":448,"briefSummary":449,"conditions":450,"keywords":452,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":73},"100633935","targeted-lens-intervention-for-myopic-anisometropia-in-children-100633935","NCT07533149","Targeted Lens Intervention for Myopic Anisometropia in Children","Clinical Investigation of Targeted Lens Intervention in the Management of Myopic Anisometropia in Children","Inclusion Criteria:\n\n1. Voluntary\n2. Informed consent of parent\u002Fguardian and assent of participant\n3. Age equal to or greater than 6 years old and less than 13 years at the time of signing informed consent and assent\n4. SER equal or less than -0.50 D and equal or greater than .5.00 D with astigmatism not more than 2.50 D\n5. Difference in SER (anisometropia) between two eyes .1.00 D\n6. Best corrected visual acuity (BCVA) better than or equal to +0.20 LogMAR in each eye\n7. Agree to wear study spectacles for .12 hours\u002Fday and 7 days\u002Fweek\n8. Willingness and ability to participate in investigation for 12 months and attend scheduled visits punctually\n9. Agree for no concurrent involvement in other myopia control treatment\n\nExclusion Criteria:\n\n1. History or presence of an ocular disease affecting refractive status\n2. History or presence of strabismus\n3. Presence of amblyopia\n4. Current or previous use of atropine and\u002For orthokeratology\n5. Known allergy to cycloplegic agents\n6. Contraindication to cycloplegic agents\n7. Cognitive or psychological vulnerability",{"count":297,"type":23},[170],"The goal of this clinical trial is to learn if our research spectacles will lower the difference in prescription (spectacles degree) between the eyes in children between 6 to 13 years old with anisometropic myopia. Anisometropic myopia is when the difference in myopia prescription between the two eyes are more than 1 diopter. The main question it aims to answer is:\n\n* How the eye responds to the research spectacles over time by measuring:\n\n  1. Change in axial length: the physical length of the eye from front to back.\n  2. Change in cycloplegic spherical equivalent refraction: an accurate measurement of the eye's prescription taken while the focusing muscles are temporarily relaxed with eye drops.\n\n     Participants will:\n* Wear the study spectacles\n* Visit Essilor R\\&D Centre and an eye clinic for follow-up sessions",[451,29],"Anisometropia",[453,454,455,456],"myopia control","anisometropia","axial length","spherical equivalent refraction","2026-04-09",{"date":373,"type":36},{"date":460,"type":23},"2026-04",{"date":462,"type":23},"2027-07",{"name":464,"class":311},"Essilor International",{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":471,"targetDuration":4,"studyType":24,"phases":473,"briefSummary":475,"conditions":476,"keywords":477,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":488},"100633096","phase-2-safety-and-efficacy-of-t10430-eye-drops-in-controlling-paediatric-myopia-progression-100633096","NCT07522242","Safety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia Progression","Principal Inclusion Criteria:\n\n1. \\- Informed consent signed and dated.\n2. \\- Male or female participant between ≥ 6 and \\\u003C 12 years old.\n3. \\- Spherical equivalent refractive error (SER) of at least -1.00D and no more than -6.00D in each eye as measured by cycloplegic autorefraction.\n4. \\- IOP \\\u003C 21mmHg in each eye.\n5. \\- Distant BCVA equal or better than 0.1 LogMAR \\[≤ 0.1 LogMAR (equivalent to ≥ 20\u002F25 Snellen)\\] in each eye.\n\nPrincipal Exclusion Criteria:\n\nOphthalmic exclusion criteria in AT LEAST ONE EYE (1-11):\n\n1. Known intolerance to administration of eye drops.\n2. Astigmatism \\> 1.50D as measured by cycloplegic autorefraction.\n3. Anisometropia ≥ 1.50D as measured by cycloplegic autorefraction.\n4. Current or history of amblyopia or manifest strabismus including intermittent tropia.\n5. Current or history of glaucoma.\n6. Current or history of significant or severe damage to the cornea.\n7. Presence of anterior segment pathology (e.g. iris malformation, cataract).\n8. Presence of posterior segment or retinal pathology (dystrophies).\n9. History of any disease or syndrome that predisposed the participant to severe myopia (e.g., Marfan syndrome, Stickler syndrome, retinopathy of prematurity).\n10. History of non-axial cause of myopia (refractive or secondary myopia).\n11. History of abnormal ocular refractive anatomy (e.g., keratoconus, keratoglobus, lenticonus, spherophakia).\n\nSystemic\u002Fnon-ophthalmic exclusion criteria (12-13):\n\n12 - Known or suspected hypersensitivity to one of the components of the IMP (T10430) or diagnostic agents used during the study (e.g., fluorescein, cycloplegic agent).\n\n13- History of or active relevant systemic condition (e.g., connective tissue disease, allergy) incompatible with the study or likely to interfere with the study results or the participant safety according to investigator's judgment.\n\n14- Specific exclusion criteria regarding sexually active individuals (14-15): Pregnancy for post-menarche participant (confirmed with a positive urine pregnancy test).\n\n15- Adolescent of childbearing potential (male\u002Ffemale) who is sexually active and is not willing to use preventive measures.\n\nExclusion criteria related to general conditions (16-21):\n\n16- Inability of participant and\u002For legal guardian(s) to understand the study procedures or to give informed consent.\n\n17- Non-compliant participant and\u002For legal guardian(s) (e.g., not willing to attend a visit or a phone call or to complete the diary, way of life interfering with compliance).\n\n18- Participation in this study at the same time as another clinical study. 19- Participation in this study within the 4 weeks after the end of a previous clinical study not related to myopia (or within 5 half-lives of the previously tested product if longer than 4 weeks).\n\n20- Participant previously randomised in this study. 21- Participant being family member of the study sites or of the Laboratoires Théa company.\n\n22- Exclusion criteria related to previous and concomitant treatments (medications\u002Fnon-medicinal therapies\u002Fprocedures): Participant with previous, current or anticipated prohibited listed treatment (or prohibited modification of treatment regimen).",{"count":472,"type":23},200,[474],"PHASE2","Axial myopia is a type of nearsightedness that happens when the eye is too long from front to back. This causes distant vision to be blurry. Axial myopia tends to start during childhood and worsens over time (as the eyes continue to grow longer). This can lead to serious eye-related conditions later in life. The aim of T10430 treatment is to stop or slow this progression during childhood and therefore, prevent more serious complications. Animal studies using drugs with a similar mechanism of action as T10430 have demonstrated positive safety results. This study aims to better understand the safety and potential effectiveness of T10430 in children with axial myopia.",[29],[478],"Paediatric myopia","2026-04-03",{"date":481,"type":36},"2026-04-13",{"date":483,"type":36},"2026-01-21",{"date":485,"type":23},"2027-11",{"name":487,"class":311},"Laboratoires Thea",10,{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":17,"sex":18,"minAge":166,"maxAge":141,"enrollmentInfo":497,"targetDuration":4,"studyType":24,"phases":499,"briefSummary":500,"conditions":501,"keywords":503,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":507,"completionDateStruct":508,"leadSponsor":510,"locationsCount":73},"100626784","visual-and-postural-behavior-in-myopic-and-non-myopic-teenagers-100626784","NCT07440134","Visual and Postural Behavior in Myopic and Non-Myopic Teenagers","Comportement Visuo-postural Des Adolescents Myopes et Non Myopes (CALYPSO)","CALYPSO","Inclusion Criteria:\n\n* Volunteer adolescent, fluent in French, able to follow protocol and read and write\n* Aged between 12 and 17 years and 6 months\n* Adolescent with no history, according to the participant and\u002For their legal representatives, of any pathology, deficit, or disorder that could interfere with visual or cognitive functions.\n* If the subject wears glasses, they must have an ophthalmic prescription dated within the last year, certifying that a consultation was carried out during the previous year\n* If the subject wears Essilor® Stellest® 1.0 lenses, they must have worn them for at least two (2) consecutive months prior to inclusion in the study.\n* If the subject is nearsighted: -6.5D ≤ equivalent sphere ≤ -0.5D with usual correction\n* If the subject is not nearsighted: -0.5 \\\u003C equivalent sphere ≤ +2.5\n\nExclusion Criteria:\n\n* Age ≤ 12 years\n* Age \\> 17 years and 6 months\n* Pregnant or breastfeeding women (Article L1121-5)\n* Persons (legal representatives or subjects) deprived of their liberty by a judicial or administrative decision and persons hospitalized without consent pursuant to Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8 and persons admitted to a health or social care facility for purposes other than research\n* Participants who are currently excluded from another study\n* All categories of persons who are particularly protected under French law are excluded from this research (Articles L1121-5 to L1121-9 of the Public Health Code)\n* Declared neurological deficit, in particular a history of epileptic pathology or sensorimotor coordination disorders, vestibular or cerebellar pathology (e.g., balance disorders)\n* Severe declared eye disease involving loss of visual field, such as glaucoma, involving loss of acuity and severe discomfort in low-light or overly bright environments, such as retinitis pigmentosa, or declared and treated dry eye syndrome.\n* Gougerot-Sjögren syndrome or declared dry eye syndrome\n* Declared aphakia or pseudophakia (intraocular implant)\n* Declared systemic pathology, medical treatment, or medication with an effect on vision\n* People with declared muscle paralysis\n* Binocular vision problems such as amblyopia, strabismus, or nystagmus\n* Children of employees or employees of Essilor International, Luxottica, GrandVision, and their subsidiaries\n* Individuals who have undergone previous refractive surgery, have a history of strabismus surgery, or have a history of any type of eye surgery",{"count":498,"type":23},100,[170],"The goal of this observational study is to learn whether different types of eyeglasses prescription and different types of lenses change how close teenagers hold objects when looking at them up close. The study includes adolescents who are non-myopic and adolescents who are myopic and wear either single-vision lenses or lenses slowing down myopia progression.\n\nThe main questions it aims to answer are:\n\nDo teenagers in these three groups use different average working distances (eye-to-object distance) during everyday tasks?\n\nDoes wearing Essilor® Stellest® lenses change working distance compared with wearing single-vision lenses?\n\nResearchers will compare the three groups to see if their working distances differ.\n\nParticipants will:\n\nComplete an initial optometric eye examination.\n\nCome for a second visit where they perform everyday activities while wearing a motion-capture system that measures how they move and how far they hold objects.",[502,29],"Teenagers",[29,504],"Ophthalmological measurements","2026-04-02",{"date":479,"type":36},{"date":479,"type":23},{"date":509,"type":23},"2027-05",{"name":464,"class":311},{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":18,"minAge":218,"maxAge":518,"enrollmentInfo":519,"targetDuration":4,"studyType":24,"phases":521,"briefSummary":522,"conditions":523,"keywords":525,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":4},"100632317","the-impact-of-a-miss-is-as-good-as-a-mile-is-compensation-necessary-for-minimal-ocular-deviation-in-myopic-laser-surgery-100632317","NCT07512115","The Impact of 'A Miss Is as Good as a Mile': Is Compensation Necessary for Minimal Ocular Deviation in Myopic Laser Surgery?","Effect of Centration Compensation on Visual Quality in VisuMax 800 SMILE for Small Kappa Angles: A Randomized Trial","Inclusion Criteria:\n\n1. Patients aged 18 to 40 years with myopia or myopic astigmatism and stable refraction for \\>=1 year, whose refractive errors fall within the treatable range of and meet the indications for SMILE surgery.\n2. Normal corneal morphology and corneal thickness meeting surgical requirements.\n3. Preoperative corrected distance visual acuity (CDVA) \\>= 1.0.\n4. Preoperative synthetic Kappa angle offset measured \\>= 0.10 mm and \\\u003C 0.20 mm.\n5. Voluntarily agree to undergo SMILE surgery on the VISUMAX 800 platform, understand the randomization scheme, and provide signed informed consent.\n\nExclusion Criteria:\n\n1. History of prior ocular surgery, significant ocular trauma, or presence of corneal or ocular diseases that may affect the safety of refractive surgery.\n2. Severe systemic diseases that may affect ocular healing or surgical safety.\n3. Females who are pregnant or lactating.\n4. Inability to cooperate as required to complete the procedure or follow-up visits.","40 Years",{"count":520,"type":23},224,[170],"The goal of this clinical trial is to evaluate the effect of intraoperative kappa-angle compensation on postoperative visual quality in patients undergoing small incision lenticule extraction (SMILE) using the VisuMax 800 platform. The study will enroll patients with myopia and a kappa-angle offset \\\u003C 0.2 mm.\n\nThe main questions it aims to answer are:\n\nDoes intraoperative kappa-angle compensation reduce postoperative higher-order aberrations after SMILE? Does kappa-angle compensation improve postoperative visual quality and refractive outcomes compared with no compensation?\n\nResearchers will compare SMILE with intraoperative kappa-angle compensation to SMILE without compensation to determine whether compensation leads to better optical quality and visual performance.\n\nParticipants will:\n\nUndergo SMILE surgery with or without intraoperative kappa-angle compensation Complete scheduled postoperative examinations at 1 week, 1 month, 3 months, and 6 months after surgery Receive measurements of visual acuity, refraction, higher-order aberrations, contrast sensitivity, and safety outcomes",[29,524],"Refractive Ametropia",[60,526,527,528,529,530],"SMILE","Refractive Surgery","Randomized Clinical Trial","Angle Kappa","VisuMax 800","2026-03-31",{"date":533,"type":36},"2026-04-06",{"date":535,"type":23},"2026-04-01",{"date":537,"type":23},"2027-05-30",{"name":419,"class":43},{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":18,"minAge":218,"maxAge":518,"enrollmentInfo":545,"targetDuration":4,"studyType":24,"phases":546,"briefSummary":547,"conditions":548,"keywords":549,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":550,"startDateStruct":551,"completionDateStruct":552,"leadSponsor":553,"locationsCount":4},"100632316","comparison-of-low--versus-high-level-angle-kappa-compensation-strategies-in-smile-using-the-visumax-800-a-randomized-clinical-trial-100632316","NCT07512102","Comparison of Low- Versus High-Level Angle Kappa Compensation Strategies in SMILE Using the VisuMax 800: A Randomized Clinical Trial","Inclusion Criteria:\n\n1. Age range: 18 - 40 years old. Patients with stable refractive status for \\>= 1 year, having myopia or myopic astigmatism, with refractive power within the range of SMILE procedure.\n2. Normal corneal morphology and corneal thickness meeting the surgical requirements.\n3. Best corrected visual acuity (CDVA) before surgery \\>= 1.0.\n4. The kappa angle-related offset coordinates (x, y) obtained before surgery, with the absolute value of either \\|x\\| or \\|yl\\| of any eye \\>= 0.20mm.\n5. Voluntary to undergo SMILE surgery on the VISUMAX800 platform, understanding the random grouping scheme and signing the informed consent form.\n\nExclusion Criteria:\n\n1. History of prior ocular surgery, significant ocular trauma, or presence of corneal or ocular diseases that may affect the safety of refractive surgery.\n2. Severe systemic diseases that may affect ocular healing or surgical safety.\n3. Females who are pregnant or lactating.\n4. Inability to cooperate as required to complete the procedure or follow-up visits.",{"count":498,"type":23},[170],"The goal of this clinical trial is to compare two intraoperative kappa-angle compensation strategies during small incision lenticule extraction (SMILE) using the VisuMax 800 platform in patients with relatively large kappa-angle offsets.\n\nAngle kappa represents the difference between the visual axis and the pupil center. In patients with a large offset, pupil-centered treatment may lead to decentration of the optical zone, which can induce higher-order aberrations and affect postoperative visual quality. The VisuMax 800 system allows intraoperative adjustment of the treatment center based on the measured offset, making different compensation strategies possible.\n\nThe main questions this study aims to answer are:\n\nDoes low kappa-angle compensation (50%) result in lower postoperative higher-order aberrations than high compensation (100%)? Does the compensation strategy influence visual acuity, refractive outcomes, contrast sensitivity, and subjective visual quality after SMILE? Are the measurements obtained from different diagnostic devices consistent when evaluating kappa-related parameters?\n\nResearchers will compare SMILE with low compensation to SMILE with high compensation to determine which strategy provides better optical quality and visual performance.\n\nParticipants will:\n\nUndergo SMILE surgery using either low or high kappa-angle compensation Complete scheduled postoperative examinations at 1 month, 3 months, and 6 months Receive measurements of visual acuity, refraction, higher-order aberrations, contrast sensitivity, and patient-reported visual outcomes Be monitored for safety outcomes and adverse events during follow-up",[29,524],[60,526,527,528,529,530],{"date":533,"type":36},{"date":535,"type":23},{"date":537,"type":23},{"name":419,"class":43},{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":18,"minAge":560,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":24,"phases":562,"briefSummary":563,"conditions":564,"keywords":565,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":73},"100631790","comparison-of-myopic-small-incision-lenticule-extraction-smile-with-visumax-500-versus-visumax-800-platforms-100631790","NCT07505264","Comparison of Myopic Small Incision Lenticule Extraction (SMILE) With VISUMAX 500 Versus VISUMAX 800 Platforms","Inclusion Criteria:\n\n* Cycloplegic spherical equivalent of \\>-1.00D\n* Refractive cylinder -2.00 D or less; anisometropia \\\u003C1.00D\n* Best spectacle corrected visual acuity (BSCVA) of 6\u002F12 or better in both eyes\n* Spherical or cylindrical error has progressed at -0.50 D or less per year from date of baseline measurement in both eyes\n* Contact lens wearers must have removed contact lenses at least 2 weeks before the baseline measurement\n* No evidence of irregular astigmatism on corneal topography in both eyes\n\nExclusion Criteria:\n\n* Progressive or unstable myopia and\u002For astigmatism\n* Clinical or corneal topographic evidence of keratoconus\n* Residual, recurrent or active ocular disease such as uveitis, severe dry eyes, severe allergic eye disease, glaucoma, visually significant cataract, and retinal disease\n* Previous corneal surgery or trauma within the corneal flap zone\n* Patent corneal vascularization within 1 mm of the corneal flap zone\n* Taking systemic medications likely to affect wound healing, such as corticosteroids and antimetabolites\n* Systemically immunocompromised or systemic disease likely to affect wound healing, such as diabetes, connective tissue disease, and severe atopy; pregnant or nursing","21 Years",{"count":498,"type":23},[170],"Small incision lenticule extraction (SMILE) procedure is a well-known procedure for the correction of myopia. The purpose of this research study is to compare the two SMILE procedures with different laser platforms (VISUMAX 500 and VISUMAX 800) used for the correction of short-sightedness. The VISUMAX 800 and VISUMAX 500 perform the same procedure, but the VISUMAX 800 is a newer platform. This study is being done to see if the newer VISUMAX 800 provides the same or better results than the VISUMAX 500.",[29],[526,566,567,568],"Visumax","Refractive surgery","RCT","2026-03-26",{"date":535,"type":36},{"date":572,"type":36},"2025-12-01",{"date":574,"type":23},"2027-06",{"name":576,"class":43},"Singapore Eye Research Institute",{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":4,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":18,"minAge":193,"maxAge":141,"enrollmentInfo":584,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":586,"conditions":587,"keywords":589,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":598,"locationsCount":73},"100537526","comparing-myopia-treatments-in-youth-defocus-spectacles-glasses-and-ortho-k-100537526","NCT06278974","Comparing Myopia Treatments in Youth: Defocus Spectacles, Glasses, and Ortho-K","A Comparative Study on the Clinical Efficacy, Quality of Life, and Cost of Use of Peripheral Defocus Spectacles, Frame Glasses, and Orthokeratology Lenses in Myopic Children and Adolescents","Inclusion Criteria:\n\n* Children aged 7-17 years.\n* Myopia between -1.00D and -6.00D; astigmatism \\\u003C±1.5D; best corrected visual acuity ≥1.0.\n* First-time spectacle wearers who use a single correction method and meet the indications for it (any one of orthokeratology lenses, single-vision frame glasses, or myopia control frame glasses)\n* Willing to participate in the entire research process and complete all the examinations, questionnaires and cost records as required.\n* Be able to maintain contact throughout the research period, such as having a fixed address and contact information.\n\nExclusion Criteria:\n\n* History of strabismus, amblyopia, refractive disparity or retinal diseases\n* Previous history of eye surgery\n* Severe psychological disorders or behavioral problems\n* History of allergy to contact lenses or contact lens care solutions",{"count":585,"type":23},90,"The research project titled \"A Comparative Study on the Clinical Efficacy, Quality of Life, and Cost of Use of Peripheral Defocus Spectacles, Frame Glasses, and Orthokeratology Lenses in Myopic Children and Adolescents\" aims to evaluate different non-surgical myopia correction methods in children. It focuses on assessing the impact of peripheral defocus spectacles, frame glasses, and orthokeratology lenses on the quality of life, clinical effectiveness, and costs associated with each method. The study is a prospective cohort study involving 90 children aged 8-17 years with myopia ranging from -1.00D to -6.00D. It aims to compare the psychological, social, and educational aspects of these correction methods, alongside their costs and clinical outcomes over a period of one year.",[29,588,147],"Cost-effectiveness Analysis",[29,590,591],"youth","glasses","2026-03-19",{"date":594,"type":36},"2026-03-23",{"date":596,"type":36},"2023-11-10",{"date":308,"type":23},{"name":599,"class":43},"He Eye Hospital"]